Medical Device Recall Improvement Act of 2025
The Medical Device Recall Improvement Act of 2025 would amend the Federal Food, Drug, and Cosmetic Act to create a standardized electronic format for medical device recall notifications. The Secretary of Health and Human Services would be required to publish the electronic recall form and required data elements within two years of enactment, and manufacturers or importers would then have to use that format when submitting recall notices to the FDA. The required information would include the manufacturer or importer’s identity and contact information, the reason for the recall, the specific device and unique device identifier, and tailored information for device user facilities, health professionals, and patients.
The bill also requires the FDA to conduct an initial review of recall notices within two business days and then tell the manufacturer or importer what information should be shared with device user facilities and health professionals. It further directs the agency to maintain a publicly accessible, downloadable electronic database of device recall notifications. In addition, the bill creates a patient-notification framework for certain higher-risk devices, including implanted, life-sustaining, life-supporting, and some pediatric-use devices, and makes failure to comply with the new notification requirements a prohibited act under federal law.
If enacted, the bill would add new sections 518B and 518C to the Federal Food, Drug, and Cosmetic Act and expand the list of prohibited acts under section 301. It would impose new federal compliance obligations on device manufacturers and importers, require FDA to establish and manage an electronic recall-notification system, and create a public database of recall information. The bill would also require recall strategies for certain devices to include patient notice, affecting how recalls are communicated to hospitals, clinicians, and patients.
Based on the text and available context, the bill appears to have a generally reform-oriented, consumer-protection sentiment, focused on improving the speed, clarity, and accessibility of recall information. There are no recorded committee transcripts or votes in the provided material, so there is no evidence of formal support or opposition in the available history. The structure of the bill suggests an emphasis on transparency and patient safety rather than controversy.
The main potential points of contention are the new compliance burdens on manufacturers and importers, the FDA’s added review and database responsibilities, and the scope of patient-notification requirements for certain device classes. Stakeholders concerned about regulatory burden may question the mandated electronic format, short review timelines, and public database requirements, while patient-safety advocates are likely to support the stronger notification and disclosure provisions. The bill also leaves the Secretary discretion over optional data elements and the exact form and manner of notifications, which could be a point of implementation debate.